Finasterida Cinfa is commonly used across therapeutic domains involving certain distressing symptoms in adult males. The medication is applied in clinical settings for conditions presenting with systemic or localized discomfort: managing the symptomatic strain associated with Benign Prostatic Hyperplasia (BPH) and addressing the gradual progression of Male Pattern Hair Loss.

In scenarios where patients experience urinary symptoms, Finasterida Cinfa provides support that helps ease the overall symptom burden, assisting with maintaining functional stability in situations where patients experience difficult urination, reduced stream force, or disruptive nocturia. The medication also plays a role in managing symptoms that create noticeable physiological strain in conditions where symptoms may intensify temporarily, which is relevant to the gradual thinning process of hereditary hair loss. The overall benefit provides support that helps ease the overall symptom burden, assisting with maintaining functional stability.

Quick Fact: Supportive Management for Urinary Symptoms
Primary Condition	Benign Prostatic Hyperplasia (BPH)
Symptom Domain	Lower Urinary Tract Symptoms (LUTS)
General Benefit	Supports functional stability and eases systemic burden

Regulatory References

1. NIH StatPearls overview

Finasterida Cinfa is officially indicated for use exclusively in adult men and is not approved for any other population. Eligibility is strictly governed by regulatory documentation.

Absolute Contraindications (Who Must Not Use)

The medicine is formally contraindicated and must not be used by the following populations:

• Women: Especially those who are or may potentially be pregnant, due to the risk of causing external genitalia abnormalities in a male fetus.
• Children and Adolescents: Use is prohibited for the pediatric population (under 18 years) as safety and efficacy have not been established.
• Hypersensitivity: Individuals with a known allergy to the active ingredient, finasteride, or any excipients.

Population-Specific Restrictions

Population Group	Regulatory Status
Hepatic (Liver) Impairment	Caution is advised; pharmacokinetics have not been studied in this group.
Renal (Kidney) Impairment	No dosage adjustment is necessary for patients with renal insufficiency.
Pregnant Women Handling	Must not handle crushed or broken tablets due to the risk of skin absorption.

Interaction Map: Interactions with other medicines and products — official regulatory information for Finasterida Cinfa

---

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	5-alpha reductase inhibitors (class restriction), CYP3A4 inhibitors, and CYP3A4 inducers (predicted pharmacokinetic effects).
Specific interacting medicines (if explicitly listed)	None with tested agents including Propranolol, Digoxin, Warfarin, Theophylline, or Glibenclamide; Doxazosin co-administration is documented without general restriction (at 5 mg dose).
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (Metabolic): Finasteride is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme.
Timing-based interaction rules (if applicable)	None: Administration is permitted with or without food; no mandatory time separation is specified for co-administered medicines.
Population-specific interaction notes (if applicable)	Hepatic Insufficiency: The effect on Finasteride pharmacokinetics has not been studied.
Interaction-related restrictions	Prohibited Co-administration: Restriction with other 5-alpha reductase inhibitors due to class effect.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents)	Low Potential for Clinically Significant Drug Interactions (with common tested agents).
Regulatory basis (EMA / FDA / etc.)	Based on official labeling from multiple government regulatory authorities, including the FDA and EMA national partners.
Interaction-context constraints (as defined in official documents)	Predicted exposure modification is constrained to co-administration with strong CYP3A4 inhibitors or inducers.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with other 5-alpha reductase inhibitors is officially restricted.
• No clinically significant interactions were identified when the medicine was co-administered with Propranolol, Digoxin, Glibenclamide, or Warfarin.
• Substances that inhibit or induce CYP3A4 are predicted to increase or decrease Finasteride plasma exposure, respectively.
• The medicine may be taken with or without food, and no time-separation rules are specified.
• The pharmacokinetics of the drug have not been evaluated in patients with hepatic insufficiency.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is characterized by a low risk of clinically significant drug-drug interactions with most co-administered agents. The profile is primarily defined by the predicted pharmacokinetic alteration based on the product's reliance on the CYP3A4 metabolic pathway. The only strict regulatory restriction is the avoidance of combination with other medicines sharing the same pharmacological classification.

Targeted Enzyme Inhibition in Androgen Pathways

Finasteride operates by acting as a highly selective competitive inhibitor of the intracellular enzyme, 5alpha-reductase Type II. This enzyme is the primary biological target, and its role is to catalyze the conversion of Testosterone into the more potent androgen, Dihydrotestosterone (DHT). By binding to the enzyme's active site, the medicine blocks this conversion, resulting in a reduction of DHT in the serum and within target tissues (up to 70–90%).

The Dihydrotestosterone (DHT) Modulatory Cascade

The subsequent decrease in DHT initiates a mechanistic cascade centered on androgen-dependent cellular activity. Since DHT is a powerful androgenic signal for cell proliferation and maintenance in specific tissues, its systemic reduction limits the activation of the Androgen Receptor. The resulting lack of stimulation alters the cellular environment, leading to the reduction of androgen-mediated cellular proliferation and supporting a progressive change in tissue morphology.

Mechanistic Limitations and Response Onset

The action is limited by the drug's minimal affinity for the Type I 5alpha-reductase enzyme, meaning DHT suppression is partial. This mechanistic constraint, along with the requirement for progressive tissue remodeling, establishes the extended period necessary for the mechanism to achieve its maximum physiological alteration following continuous enzyme inhibition.

How to Use Finasterida Cinfa — Administration Guidelines

Finasteride is administered solely by the oral route as a film-coated tablet. The usage protocol is defined by the following instructions, ensuring consistent and correct administration.

The dosage is indication-specific: the standard dose for Benign Prostatic Hyperplasia (BPH) is 5 mg taken once daily, while the dose for male pattern hair loss is 1 mg taken once daily. Taking doses higher than the standard recommendation does not enhance the therapeutic effect.

The required frequency is once daily (qDay) to maintain consistent drug levels. The tablet may be administered with or without food. It is recommended to take the tablet at the same time each day to support adherence to the daily schedule. If a dose is missed, the patient should skip the missed dose and resume the regular schedule; two doses should never be taken at once.

The film-coated tablet must be swallowed whole and must not be crushed, broken, or chewed. This condition is critical for proper administration.

Treatment for certain conditions requires long-term continuity. For male pattern hair loss, a minimum of three months of continuous daily administration is typically necessary before any effect is observed. Guidelines state that no dosage adjustment is required for older adults or patients with renal impairment, which simplifies the dosing protocol for these populations. The medicine is not indicated for use in children or adolescents.

Finasteride is a compound studied for its effects in Benign Prostatic Hyperplasia (BPH) and Androgenetic Alopecia (AGA). Clinical research focuses on its ability to inhibit the type II 5-alpha reductase enzyme, which reduces the conversion of testosterone to dihydrotestosterone (DHT). Lowering DHT levels is the key mechanism investigated in trials for both conditions.

Efficacy Findings

Clinical trials have evaluated finasteride at two primary dosage levels, yielding distinct results for each indication:

Indication	Dosage Level	Primary Study Outcomes	Long-Term Data
BPH	5 mg/day	Demonstrated significant improvement in lower urinary tract symptoms and median prostate volume reduction (up to 25%) over 2-4 years compared to placebo.	Long-term (up to 6 years) studies have shown sustained symptomatic improvement and a reduced risk of acute urinary retention and surgical intervention.
AGA	1 mg/day	Studies reported that a significant proportion of men maintained or increased hair count over 1-2 years, with improvements noted in patient and investigator assessments of hair growth.	Continued use is associated with maintaining benefits, with the reversal of effect typically observed upon discontinuation of treatment within 12 months.

Safety and Tolerability Profiles

In studies for both BPH and AGA, the compound has generally been reported as well-tolerated. However, common adverse events included sexual dysfunction, such as decreased libido, erectile dysfunction, and ejaculatory disorder, reported in a small percentage of patients. These events often resolved upon discontinuation of therapy. Due to its impact on prostate-specific antigen (PSA) levels, regular monitoring of PSA is a standard procedure in BPH management studies, as finasteride can reduce PSA levels by approximately 50%.

Common questions about Finasterida Cinfa (FAQ)

Q: Can Finasterida Cinfa affect my mood or energy levels?

Official product information notes that side effects related to mood have been reported, which can include depressed mood and depression. Fatigue or low energy (asthenia) is also listed as an adverse reaction, particularly when used alongside certain other treatments.

Q: Can Finasterida Cinfa cause liver problems?

While there is no direct regulatory statement that the medicine causes new liver damage in healthy individuals, caution is advised for patients who already have existing hepatic impairment or liver problems. Official documents state that the drug’s processing by the body has not been fully evaluated in individuals with liver impairment.

Q: Is Finasterida Cinfa suitable for women who are not pregnant?

According to the official prescribing information, this medicine is indicated only for use in adult men. It is specifically contraindicated, meaning it must not be used, by women.

Q: Is it okay to stop taking Finasterida Cinfa suddenly?

Official data indicates that the therapeutic effects of the medicine on hair loss generally begin to reverse if treatment is stopped, with benefits typically disappearing within 12 months after discontinuation. Discontinuing or changing the schedule of any medication is a decision made in consultation with a prescribing healthcare provider.

Q: Has Finasterida Cinfa been studied in elderly patients?

The drug’s properties have been studied in men over 70 years of age. Regulatory documents show that while the rate at which the drug is cleared from the body is slightly slower in older men, this is not considered a significant clinical finding. Therefore, no dosage adjustments are typically needed for older patients based on this factor alone.

Q: What should I do if I suspect an allergic reaction to Finasterida Cinfa?

Product information advises that hypersensitivity reactions have been reported in connection with this medicine. These reactions can include swelling of the lips, tongue, or face (angioedema). If any symptoms of a severe or suspected allergic reaction occur, immediate attention from a healthcare provider is warranted.

Q: Is Finasterida Cinfa known to interact with herbal supplements?

Official regulatory information cautions that any substance that affects the CYP3A4 enzyme system in the body may potentially change the level of the drug in the bloodstream. While specific herbal supplements are not universally listed, this general warning highlights the possibility of interaction.

Q: Can Finasterida Cinfa be taken by people with high blood pressure?

The medicine has been studied for benign prostatic hyperplasia (BPH) in combination with medications that treat high blood pressure (like doxazosin). Regulatory documents do not state a general, official contraindication for using this medicine in patients who have high blood pressure.

Q: Does Finasterida Cinfa work for hair loss in all areas of the scalp?

The medicine is indicated for treating male pattern hair loss, also known as androgenetic alopecia. Clinical studies focusing on the indication for male pattern hair loss primarily examined the effects on the mid-scalp and the crown area (vertex) of the head. Efficacy for hair loss in all other areas of the scalp has not been definitively established in all regulatory data.

Q: What does the term 'endocrine-disrupting' mean in relation to Finasterida Cinfa?

Finasteride is classified as a selective hormone modulator because it acts as a competitive inhibitor of the 5-alpha reductase Type II enzyme. This means it works by blocking the conversion of the hormone testosterone into a more potent form called dihydrotestosterone (DHT), thereby modulating the endocrine (hormone) system.

Q: What evidence exists about the use of Finasterida Cinfa in younger adults?

Regulatory documents state that the safety and effectiveness of the medicine have not been established in the pediatric population (individuals under 18 years old). The medicine is therefore not indicated for use in younger adults under the age of 18.

Q: Does Finasterida Cinfa carry a risk of dizziness or affect driving ability?

Dizziness has been reported as an adverse event in clinical trials, especially when used alongside certain other medications. While the medicine does not typically carry a general warning against driving, regulatory documents mention the possibility of dizziness.

Q: Is Finasterida Cinfa a controlled substance?

Finasteride is regulated as a prescription-only medicine (POM). However, it is not listed as a controlled substance under the US Drug Enforcement Administration (DEA) scheduling system.

Q: How long does Finasterida Cinfa stay in the body after stopping treatment?

The medicine is absorbed rapidly by the body. In adult men, the mean half-life (the time it takes for half the drug to be eliminated from the bloodstream) is approximately 5 to 6 hours. Most of the medicine and its inactive components are excreted from the body via urine and feces within a few days.

Q: What is the purpose of Finasterida Cinfa for prostate issues?

The medicine is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men who have an enlarged prostate. Its indication is for treating symptomatic BPH to improve symptoms and reduce the risk of acute urinary retention and the need for surgery.

Finasterida Cinfa must be stored in its original, tightly closed container and kept out of the reach of children. The product requires storage at room temperature, typically specified as between 15 C to 30 C (59 F to 86 F), and should be protected from excessive heat and moisture.

Handling and Disposal

The tablets are film-coated and must not be crushed or broken. Women who are pregnant or may potentially be pregnant must not handle damaged tablets due to the risk of dermal absorption. The medicine should not be used after the expiration date.

Unused or expired Finasterida Cinfa must not be disposed of via household waste or wastewater. It should be discarded according to local regulations or a pharmacy take-back program.